PMID- 38410023
OWN - NLM
STAT- Publisher
LR  - 20240227
IS  - 2233-6087 (Electronic)
IS  - 2233-6079 (Linking)
DP  - 2024 Feb 27
TI  - Efficacy and Safety of IDegAsp in a Real-World Korean Population with Type 2 
      Diabetes Mellitus.
LID - 10.4093/dmj.2023.0297 [doi]
AB  - BACKGROUND: This study investigated the real-world efficacy and safety of insulin 
      degludec/insulin aspart (IDegAsp) in Korean adults with type 2 diabetes mellitus 
      (T2DM), whose insulin treatment was switched to IDegAsp. METHODS: This was a 
      multicenter, retrospective, observational study comprising two 26-week treatment 
      periods, before and after switching to IDegAsp, respectively. Korean adults with 
      uncontrolled T2DM treated with basal or premix insulin (+/-oral antidiabetic drugs) 
      were enrolled. The primary objective was to compare the degree of glycosylated 
      hemoglobin (HbA1c) change in each 26-week observation period. The analyses 
      included changes in HbA1c, fasting plasma glucose (FPG), body weight, proportion 
      of participants achieving HbA1c <7.0%, hypoglycemic events, and total daily 
      insulin dose (ClinicalTrials.gov, number NCT04656106). RESULTS: In total, 196 
      adults (mean age, 65.95 years; mean T2DM duration, 18.99 years) were analyzed. 
      The change in both HbA1c and FPG were significantly different between the 
      pre-switching and the post-switching period (0.28% vs. -0.51%, P<0.001; 5.21 
      mg/dL vs. -23.10 mg/dL, P=0.005), respectively. After switching, the rate of 
      achieving HbA1c <7.0% was significantly improved (5.10% at baseline vs. 11.22% 
      with IDegAsp, P=0.012). No significant differences (before vs. after switching) 
      were observed in body weight change, and total daily insulin dose. The rates of 
      overall and severe hypoglycemia were similar in the two periods. CONCLUSION: In 
      real-world clinical practice in Korea, the change of insulin regimen to IDegAsp 
      was associated with an improvement in glycemic control without increase of 
      hypoglycemia, supporting the use of IDegAsp for patients with T2DM uncontrolled 
      with basal or premix insulin.
FAU - Kang, Shinae
AU  - Kang S
AD  - Division of Endocrinology, Department of Internal Medicine, Gangnam Severance 
      Hospital, Yonsei University College of Medicine, Seoul, Korea.
FAU - Ahn, Yu-Bae
AU  - Ahn YB
AD  - Division of Endocrinology and Metabolism, Department of Internal Medicine, St. 
      Vincent's Hospital, College of Medicine, The Catholic University of Korea, Seoul, 
      Korea.
FAU - Oh, Tae Keun
AU  - Oh TK
AD  - Department of Internal Medicine, Chungbuk National University Hospital, Chungbuk 
      National University College of Medicine, Cheongju, Korea.
FAU - Lee, Won-Young
AU  - Lee WY
AD  - Division of Endocrinology and Metabolism, Department of Internal Medicine, 
      Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, 
      Korea.
FAU - Chun, Sung Wan
AU  - Chun SW
AD  - Division of Endocrinology and Metabolism, Department of Internal Medicine, 
      Soonchunhyang University Cheonan Hospital, Soonchunhyang University College of 
      Medicine, Cheonan, Korea.
FAU - Bae, Boram
AU  - Bae B
AD  - Novo Nordisk Pharma Korea Limited, Seoul, Korea.
FAU - Dahaoui, Amine
AU  - Dahaoui A
AD  - Novo Nordisk Region Asia Pacific, Dubai, United Arab Emirates.
FAU - Jeong, Jin Sook
AU  - Jeong JS
AD  - Novo Nordisk Pharma Korea Limited, Seoul, Korea.
FAU - Jung, Sungeun
AU  - Jung S
AD  - Novo Nordisk Region Asia Pacific, Dubai, United Arab Emirates.
FAU - Jang, Hak Chul
AU  - Jang HC
AD  - Department of Internal Medicine, Seoul National University Bundang Hospital, 
      Seoul National University College of Medicine, Seongnam, Korea.
LA  - eng
SI  - ClinicalTrials.gov/NCT04656106
PT  - Journal Article
DEP - 20240227
PL  - Korea (South)
TA  - Diabetes Metab J
JT  - Diabetes & metabolism journal
JID - 101556588
SB  - IM
OTO - NOTNLM
OT  - Databases, factual
OT  - Diabetes mellitus, type 2
OT  - Glycemic control
OT  - Hypoglycemia
OT  - Insulin degludec, insulin aspart drug combination
EDAT- 2024/02/27 06:45
MHDA- 2024/02/27 06:45
CRDT- 2024/02/27 02:46
PHST- 2023/08/24 00:00 [received]
PHST- 2023/11/22 00:00 [accepted]
PHST- 2024/02/27 06:45 [medline]
PHST- 2024/02/27 06:45 [pubmed]
PHST- 2024/02/27 02:46 [entrez]
AID - dmj.2023.0297 [pii]
AID - 10.4093/dmj.2023.0297 [doi]
PST - aheadofprint
SO  - Diabetes Metab J. 2024 Feb 27. doi: 10.4093/dmj.2023.0297.